Affinia Therapeutics today announced that new preclinical data will be presented in an oral and poster sessions at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, being held May 16-20, 2023 in Los Angeles, CA.
| WALTHAM, Mass., May 3, 2023 /PRNewswire/ -- Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and prevalent devastating diseases, today announced that new preclinical data will be presented in an oral and poster sessions at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, being held May 16-20, 2023 in Los Angeles, CA.
Presentation details are as follows: Oral presentation Title: Structure-Activity Relationships Guided Engineering of AAV Capsid with Optimized Skeletal Muscle, Cardiac Muscle, and CNS Tropism Poster presentations Title: Limitations of Marmosets as an Animal Model for AAV Mediated Liver Gene Transfer Title: Improvement of Yield and Critical Quality Attributes Through Process Development of a Novel Adeno-Associated Viral Vector Capsid (Anc80L65) Abstracts can be accessed via the conference website at https://annualmeeting.asgct.org/abstracts. About Affinia Therapeutics
SOURCE Affinia Therapeutics |
View original content to download multimedia:
